文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌高剂量率近距离放疗推量与IMRT顺序对早期毒性影响

Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-05-13

单中心回顾性分析比较中危及以上前列腺癌患者接受高剂量率近距离放疗(HDR-BT)推量 upfront 与调强放疗(IMRT)upfront 联合雄激素剥夺治疗(ADT)的早期毒性。结论提示两种顺序均可接受,需更长随访评估晚期毒性和长期疾病控制。

要点

  • 中危及以上前列腺癌HDR-BT推量 upfront与IMRT upfront联合ADT的GI/GU毒性无显著差异。
  • 3级及以上GI或GU毒性发生率<1%,两组急性及晚期毒性相似。
  • 治疗顺序选择基于医生偏好,且与治疗年份相关,需更长随访评估晚期毒性和疾病控制。

核心结论

  • 中危及以上前列腺癌患者接受HDR-BT推量 upfront与IMRT upfront联合ADT的GI/GU毒性无显著差异,两种顺序均可接受。

主要发现

  • 两组基线患者/疾病特征及治疗因素均衡,但治疗顺序因治疗年份不同存在差异。
  • 总体3级及以上GI或GU毒性发生率<1%,两组急性或晚期GI或GU毒性无显著差异。

关键数值与推荐

  • IMRT剂量通常为45 Gy分25次照射前列腺及精囊腺±盆腔淋巴结。
  • HDR-BT剂量为15 Gy单次,于IMRT前或后约3周 delivery。
  • 生化复发按ASTRO定义,GI和GU毒性按CTCAE v5.0分级,P值<0.05为显著。

临床怎么用

  • 对于中危及以上前列腺癌,HDR-BT推量 upfront或IMRT upfront联合ADT均可作为合理选择,顺序可基于医生偏好。

局限性

  • 单中心回顾性设计,样本量有限,中位随访26.0个月较短,需更长随访评估晚期毒性和长期疾病控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We present the first report comparing early toxicity outcomes with high-dose rate brachytherapy (HDR-BT) boost upfront versus intensity modulated RT (IMRT) upfront combined with androgen deprivation therapy (ADT) as definitive management for intermediate risk or higher prostate cancer. METHODS AND MATERIALS: We reviewed all non-metastatic prostate cancer patients who received HDR-BT boost from 2014 to 2019. HDR-BT boost was offered to patients with intermediate-risk disease or higher. ADT use and IMRT target volume was based on NCCN risk group. IMRT dose was typically 45 Gy in 25 fractions to the prostate and seminal vesicles ± pelvic lymph nodes. HDR-BT dose was 15 Gy in 1 fraction, delivered approximately 3 weeks before or after IMRT. The sequence was based on physician preference. Biochemical recurrence was defined per ASTRO definition. Gastrointestinal (GI) and Genitourinary (GU) toxicity was graded per CTCAE v5.0. Pearson Chi-squared test and Wilcoxon tests were used to compare toxicity rates. P-value < 0.05 was significant. RESULTS: Fifty-eight received HDR-BT upfront (majority 2014-2016) and 57 IMRT upfront (majority 2017-2018). Median follow-up was 26.0 months. The two cohorts were well-balanced for baseline patient/disease characteristics and treatment factors. There were differences in treatment sequence based on the year in which patients received treatment. Overall, rates of grade 3 or higher GI or GU toxicity were <1%. There was no significant difference in acute or late GI or GU toxicity between the two groups. CONCLUSION: We found no significant difference in GI/GU toxicity in intermediate-risk or higher prostate cancer patients receiving HDR-BT boost upfront versus IMRT upfront combined with ADT. These findings suggest that either approach may be reasonable. Longer follow-up is needed to evaluate late toxicity and long-term disease control.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Roy A, Brenneman RJ, Hogan J, et al. Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis. Clin Transl Radiat Oncol. 2021. PMID: 34136665. doi:10.1016/j.ctro.2021.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。